Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator

Circulation

Volumn 95, Issue 1, 1997, Pages 46-52

  Biessen, Erik A L ^a   Van Teijlingen, Marco ^a   Vietsch, Helene ^a   Barrett Bergshoeff, Marrie M ^b   Bijsterbosch, Martin K ^a   Rijken, Dingeman C ^b   Van Berkel, Theo J C ^a   Kuiper, Johan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b TNO   (Netherlands)

Author keywords

cluster mannoside; GST RAP; plasminogen activators; thrombolysis

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; MANNOSE RECEPTOR; MANNOSIDE; RECEPTOR PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FIBRINOLYSIS; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031014592     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.1.46     Document Type: Article

References (15)

1. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cell in culture. J Biol Chem. 1981;256:7035-7041.
2. Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators: tissue degradation and cancer. Adv Cancer Res. 1985;44:139-266.
3. Collen D, Lijnen HR, Todd PA, Goa KL. Tissue-type plasminogen activator: a review of its pharmacological and therapeutic use as a thrombolytic agent. Drugs. 1989;38:346-388.
4. Simoons ML. Thrombolytic therapy in acute myocardial infarction. Annu Rev Med. 1989;40:181-200.
5. The GUSTO Investigators. An international randomized trial comparing thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
6. Emeis JJ, Van den Hoogen CM, Jense D. Hepatic clearance of tissue-type plasminogen activator (t-PA) in rats. Thromb Haemost. 1985;54:661-664.
7. Kuiper J, Otter M, Rijken DC, Van Berkel TJC. Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. J Biol Chem. 1988;263:18220-18224.
8. Mohler MA, Tate K, Bringham TS, Fuller G, Keyt B, Vehar G, Hotchkiss AJ. Circulatory metabolism of recombinant tissue-type plasminogen activator in monkeys and rabbits. Fibrinolysis. 1988;2:17-23.
9. Nilsson S, Einarsson M, Ekvärn S, Häggroth L, Matsson C. Turnover of tissue-type plasminogen activator in normal and hepatectomized rabbits. Thromb Res. 1985;39:511-521.
10. Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemost. 1981;46:658-661.
11. Smedsrod B, Einarsson M. Clearance of tissue-type plasminogen by mannose and galactose receptors in the liver. Thromb Haemost. 1990;63:60-66.
12. Einarsson M, Smedsrod B, Pertoft H. Uptake and degradation of tissue-type plasminogen activator in rat liver. Thromb Haemost. 1988;59:474-479.
13. Bu G, Warshawsky I, Schwartz AL. Cellular receptors for the plasminogen activators. Blood. 1994;83:3427-3436.
14. Noorman F, Braat EAM, Rijken DC. Degradation of tissue-type plasminogen activator by human monocyte-derived macrophages is mediated by the mannose receptor and by the low-density lipoprotein receptor-related protein. Blood. 1995;86:3421-3427.
15. 2MR is a hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci U S A. 1992;89:7427-7431.